Related Experiment Video
Updated: May 5, 2026
09:22
In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein
Published on: January 2, 2015
18.1K
Correction: Dominguez-Meijide et al. Pharmacological Modulators of Tau Aggregation and Spreading. Brain Sci. 2020,
Antonio Dominguez-Meijide1,2, Eftychia Vasili1, Tiago Fleming Outeiro1,3,4
1Department of Experimental Neurodegeneration, Center for Biostructural Imaging of Neurodegeneration, University Medical Center Goettingen, 37073 Goettingen, Germany.
Brain Sciences
|September 28, 2024
Abstract:
There was an error in the original publication [...].
Insights
An error in the original publication requires correction. This erratum addresses the inaccuracies to ensure the scientific record is accurate.
Area of Science:
- Scientific Publishing
- Publication Ethics
Context:
- Original publication contained errors.
- Need for accurate scientific record.
Purpose:
- To correct errors in the original publication.
- To provide accurate information.
Summary:
- This erratum corrects specific errors found in the original publication.
- Ensures the integrity of the published scientific data.
Impact:
- Maintains credibility of scientific literature.
- Prevents misinformation in the research community.
Related Concept Videos
03:03Amyloid Fibrils
10.3K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
10.3K
01:22Alzheimer's Disease: Treatment
1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K